AU1047002A - 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds - Google Patents

17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Info

Publication number
AU1047002A
AU1047002A AU1047002A AU1047002A AU1047002A AU 1047002 A AU1047002 A AU 1047002A AU 1047002 A AU1047002 A AU 1047002A AU 1047002 A AU1047002 A AU 1047002A AU 1047002 A AU1047002 A AU 1047002A
Authority
AU
Australia
Prior art keywords
compounds
production
pharmaceutical compositions
compositions containing
methylene steroids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU1047002A
Inventor
Bernd Menzenbach
Walter Elger
Peter Droescher
Alexander Hillisch
Gunter Kaufmann
Hans-Udo Schweikert
Gerd Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenapharm GmbH and Co KG
Original Assignee
Jenapharm GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm GmbH and Co KG filed Critical Jenapharm GmbH and Co KG
Publication of AU1047002A publication Critical patent/AU1047002A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to 17-Methylene steroids. Method for the production thereof and pharmaceutical compositions containing these compounds. The inventive compounds have an active profile with a hybrid character of such that they act as inhibitors of the 5 alpha -reductase and, at the same time, as gestagens. Said compounds are thus suited for treating medical disorders that, in men and women, are a result of an increased androgen level in certain organs and tissues. The inventive compounds combined with other hormonal substances such as estrogen, testosterone or a potent androgen are suited as contraceptives for women and men.
AU1047002A 2000-09-04 2001-08-29 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds Pending AU1047002A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10043846A DE10043846A1 (en) 2000-09-04 2000-09-04 17-methylene steroids, process for their preparation and pharmaceutical compositions containing them
PCT/EP2001/009943 WO2002019971A1 (en) 2000-09-04 2001-08-29 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Publications (1)

Publication Number Publication Date
AU1047002A true AU1047002A (en) 2002-03-22

Family

ID=7655148

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002210470A Ceased AU2002210470B2 (en) 2000-09-04 2001-08-29 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
AU1047002A Pending AU1047002A (en) 2000-09-04 2001-08-29 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2002210470A Ceased AU2002210470B2 (en) 2000-09-04 2001-08-29 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Country Status (29)

Country Link
EP (1) EP1423407B1 (en)
JP (1) JP2004513084A (en)
KR (1) KR100530816B1 (en)
CN (1) CN1262560C (en)
AT (1) ATE319733T1 (en)
AU (2) AU2002210470B2 (en)
BG (1) BG107594A (en)
BR (1) BR0113618A (en)
CA (1) CA2421302C (en)
DE (2) DE10043846A1 (en)
DK (1) DK1423407T3 (en)
EA (1) EA006387B1 (en)
EE (1) EE05186B1 (en)
ES (1) ES2260294T3 (en)
HK (1) HK1060135A1 (en)
HR (1) HRP20030256A2 (en)
HU (1) HUP0300936A3 (en)
IL (2) IL154666A0 (en)
ME (1) MEP14408A (en)
MX (1) MXPA03001912A (en)
NO (1) NO325012B1 (en)
NZ (1) NZ524485A (en)
PL (1) PL360669A1 (en)
PT (1) PT1423407E (en)
RS (1) RS50305B (en)
SK (1) SK286757B6 (en)
UA (1) UA74592C2 (en)
WO (1) WO2002019971A1 (en)
ZA (1) ZA200301715B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141984A1 (en) 2001-08-28 2003-03-20 Jenapharm Gmbh New 17-methylene-4-azasteroids
US7199115B2 (en) 2004-04-19 2007-04-03 Schering Ag 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them
DE202007019049U1 (en) * 2007-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Use of a gestagen in combination with an estrogen for the prophylaxis of lactose intolerance in oral contraception

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611773A (en) * 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US3146239A (en) * 1957-09-23 1964-08-25 Syntex Corp 4-halo-19-nor-progesterone
US3232960A (en) * 1959-10-08 1966-02-01 Upjohn Co 3-keto-4-fluoro- and 3-keto-4,4-difluorosteroids and process
US3661940A (en) * 1970-04-13 1972-05-09 Sandoz Ag Derivatives of 21-methyl-19-norpregnanes
US4389345A (en) * 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
AU2001268661A1 (en) * 2000-06-27 2002-01-08 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase

Also Published As

Publication number Publication date
CN1452628A (en) 2003-10-29
RS50305B (en) 2009-09-08
KR100530816B1 (en) 2005-11-25
AU2002210470B2 (en) 2006-07-20
MEP14408A (en) 2010-06-10
YU16403A (en) 2006-05-25
IL154666A0 (en) 2003-09-17
EP1423407A1 (en) 2004-06-02
HUP0300936A2 (en) 2003-11-28
KR20030028836A (en) 2003-04-10
CA2421302C (en) 2007-08-14
EA200300322A1 (en) 2003-10-30
IL154666A (en) 2008-12-29
NZ524485A (en) 2005-11-25
CA2421302A1 (en) 2003-03-03
HUP0300936A3 (en) 2010-01-28
DK1423407T3 (en) 2006-07-03
MXPA03001912A (en) 2004-07-08
EE200300087A (en) 2005-02-15
HRP20030256A2 (en) 2005-10-31
DE10043846A1 (en) 2002-04-04
WO2002019971A9 (en) 2002-08-08
SK2442003A3 (en) 2003-08-05
HK1060135A1 (en) 2004-07-30
NO20030989D0 (en) 2003-03-03
CN1262560C (en) 2006-07-05
NO20030989L (en) 2003-05-02
BG107594A (en) 2003-09-30
NO325012B1 (en) 2008-01-14
ZA200301715B (en) 2004-08-13
UA74592C2 (en) 2006-01-16
EP1423407B1 (en) 2006-03-08
PT1423407E (en) 2006-07-31
EE05186B1 (en) 2009-06-15
WO2002019971A1 (en) 2002-03-14
ATE319733T1 (en) 2006-03-15
JP2004513084A (en) 2004-04-30
ES2260294T3 (en) 2006-11-01
PL360669A1 (en) 2004-09-20
BR0113618A (en) 2003-07-15
EA006387B1 (en) 2005-12-29
DE50109175D1 (en) 2006-05-04
SK286757B6 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
HUP0102483A2 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
HK1054332A1 (en) Novel topical oestroprogestational compositions with systemic effect
WO2002058706A3 (en) Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
ATE293979T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SYNTETHICALLY NATURAL PROGESTERONE AND ESTRADIOL AND METHOD FOR PRODUCING THE SAME
DE60115274D1 (en) USE OF ANTIPROGESTINES FOR PROPHYLAXIS AND TREATMENT OF HORMONE-RELATED DISEASES
IL125821A0 (en) A pharmaceutical composition containing dehydroepiandrosterone and aromatase inhibitors and use thereof
SG154323A1 (en) Estrogen replacement therapy
AU1047002A (en) 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
WO2002020000A3 (en) Combined estrogen blockade of the breast with exemestane and raloxifene
MXPA05008347A (en) Compositon comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis.
WO2000067708A3 (en) Oral steroidal hormone compositions and methods of use
Whitehead Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data
UA85190C2 (en) PROCESS FOR THE SYNTHESIS OF PURE D-(17α)-13-ETHYL-17-HYDROXY-18,19-DINORPREGN-4-ENE-20-YNE-3-ONE-3E- AND -3Z-OXIME ISOMERS AND THE MIXTURE OF ISOMERS, AND USE OF THOSE ISOMERS
WO2003103614A3 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AR048829A1 (en) 17ALFA - FLUOROSTEROIDS WITH INHIBITING ACTIVITY OF 5 ALFA-REDUCTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CANCER DISEASES INFLUENCED BY ANDROGENS.
DE59907558D1 (en) AGENTS FOR STABILIZING FOOD AND COSMETIC AGENTS AND METHOD FOR THE PRODUCTION THEREOF
WO2003045971A3 (en) Solvates of 3.beta., 28-diacetoxy-18-oxo-19, 20, 21, 29, 30-pentanorlupan-22-oic acid, processes for their preparation and pharmaceutical compositions thereof
BR0016092A (en) Compound, use of a compound kit for hormonal contraception in a male, and method of treatment